Brokers Set Expectations for Delcath Systems Q1 Earnings

Delcath Systems, Inc. (NASDAQ:DCTH) – Stock analysts at HC Wainwright issued their Q1 2027 earnings per share (EPS) estimates for Delcath Systems in a research note issued on Friday, August 7th. HC Wainwright analyst S. Ramakanth anticipates that the company will earn ($0.05) per share for the quarter. HC Wainwright has a “Buy” rating and a $32.00 price target on the stock. The consensus estimate for Delcath Systems’ current full-year earnings is ($0.88) per share. HC Wainwright also issued estimates for Delcath Systems’ Q2 2027 earnings at $0.12 EPS, Q3 2027 earnings at $0.00 EPS and Q4 2027 earnings at $0.02 EPS.

Other analysts have also issued reports about the stock. Wall Street Zen raised shares of Delcath Systems from a “hold” rating to a “buy” rating in a research note on Saturday. BTIG Research boosted their price target on shares of Delcath Systems from $17.00 to $21.00 and gave the company a “buy” rating in a report on Thursday, August 6th. Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Delcath Systems in a research report on Friday. Finally, Zacks Research upgraded shares of Delcath Systems from a “strong sell” rating to a “hold” rating in a research note on Tuesday, July 7th. Five research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $23.17.

Delcath Systems Trading Up 10.3%

DCTH opened at $16.67 on Monday. The company has a market capitalization of $578.45 million, a price-to-earnings ratio of 1,668.67 and a beta of 0.52. Delcath Systems has a 12-month low of $8.12 and a 12-month high of $16.69. The business’s fifty day simple moving average is $12.48 and its 200-day simple moving average is $10.92.

Delcath Systems (NASDAQ:DCTH) last issued its earnings results on Thursday, August 6th. The company reported $0.07 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.09) by $0.16. Delcath Systems had a return on equity of 0.46% and a net margin of 0.56%.The business had revenue of $29.13 million during the quarter, compared to analyst estimates of $26.25 million.

Hedge Funds Weigh In On Delcath Systems

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Nantahala Capital Management LLC purchased a new position in shares of Delcath Systems in the 3rd quarter worth approximately $7,164,000. Marshall Wace LLP bought a new position in shares of Delcath Systems during the 2nd quarter worth approximately $6,572,000. Rosalind Advisors Inc. lifted its position in Delcath Systems by 13.8% during the second quarter. Rosalind Advisors Inc. now owns 3,300,389 shares of the company’s stock valued at $44,885,000 after acquiring an additional 400,000 shares during the last quarter. Goldman Sachs Group Inc. lifted its position in Delcath Systems by 116.0% during the fourth quarter. Goldman Sachs Group Inc. now owns 587,678 shares of the company’s stock valued at $5,936,000 after acquiring an additional 315,583 shares during the last quarter. Finally, Lane Generational LLC acquired a new stake in Delcath Systems in the fourth quarter valued at approximately $1,997,000. Hedge funds and other institutional investors own 61.12% of the company’s stock.

Delcath Systems Company Profile

Delcath Systems, Inc is a specialty pharmaceutical and medical technology company focused on the development and commercialization of its proprietary Hepatic CHEMOSAT® Delivery System, designed to deliver high-dose chemotherapeutic agents directly to the liver while minimizing systemic exposure. The company’s core technology performs isolated hepatic perfusion, enabling oncologists to administer concentrated melphalan to patients with primary and metastatic liver tumors, including those arising from ocular melanoma.